Navigation Links
Fate Therapeutics Announces First Patient Treated in Phase 1b Clinical Trial of FT1050 for Hematopoietic Stem Cell Support
Date:5/27/2009

Small Molecule Stem Cell Modulator Administered in Dual Cord Blood Transplant for Hematologic Malignancy

LA JOLLA, Calif., May 27 /PRNewswire/ -- Fate Therapeutics, Inc. announced today that the first patient has been treated in a Phase 1b clinical trial of FT1050, a small molecule Stem Cell Modulator (SCM) designed to increase hematopoietic stem cell (HSC) number and function through its activation of key pathways that guide cell fate. The study, which is being conducted at the Dana-Farber Cancer Institute in Boston, Massachusetts, will determine the safety and tolerability of introducing FT1050 during the standard course of dual umbilical cord blood transplant in adult patients with hematologic malignancies, such as leukemia and lymphoma, who have undergone nonmyeloablative conditioning therapy. Fate Therapeutics is developing FT1050 to improve the overall efficiency of HSC treatment by enhancing HSC proliferation and homing to the bone marrow.

"The mission of Fate Therapeutics is to develop small molecules and biologics that modulate adult stem cells within the body for regenerative medicine," said Paul Grayson, president and CEO of Fate Therapeutics. "As our first SCM clinical candidate, FT1050 represents the initial step in our approach - using a small molecule to treat cells ex vivo but creating an in vivo regenerative effect. With FT1050, we are trying to affect stem cell biology in the body, improving the reconstitution of a patient's blood and immune system."

"For patients who need hematopoietic stem cell support, time is of the essence," said Corey Cutler M.D., M.P.H., F.R.C.P.C., assistant professor of medicine, Dana-Farber and Harvard Medical School, and leader of the clinical study. "However, many patients do not have a suitably matched donor, either from a sibling or from an unrelated volunteer in t
'/>"/>

SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Rescheduling of hydrocodone combination ... the pain market, according to a new primary ... firm providing market research and consultation exclusively in ... - http://photos.prnewswire.com/prnh/20141021/153440 In ... hydrocodone combination products from Schedule III to Schedule ...
(Date:10/22/2014)... Antigen Discovery Inc. (ADi), a privately held ... the receipt of a National Institutes of Health (NIH) ... Institute of Dental and Craniofacial Research (NIDCR). The one-year ... Protein Microarray Chip, which will contain every protein in ... in the development of safe and effective vaccines and ...
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ... health trackers for themselves and their kids, according to ... Report: Health & Fitness Go Mobile for Moms, the ... Series. BabyCenter, the number 1 pregnancy and parenting web ... that 55 percent of moms surveyed say they can,t ...
Breaking Medicine Technology:Hydrocodone: Rescheduled, Repositioned & Reinvented 2Hydrocodone: Rescheduled, Repositioned & Reinvented 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4
... Israel, May 5, 2011 InspireMD, Inc. (OTC BB: NSPR) ... protective stent system, announced today that it has been approved ... Bulletin Board (OTCBB) under the symbol "NSPR". In ... PIPE offering in which (i) it raised approximately $9.0 million ...
... May 5, 2011 Spring Bank Pharmaceuticals today ... National Institute of Health, National Institute of Allergy and ... novel, orally bioavailable agent for the treatment of Hepatitis B ... award, Spring Bank Pharmaceuticals will receive $3.9 million over five ...
Cached Medicine Technology:InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 2InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 3InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 4InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR" 5Spring Bank Pharmaceuticals Awarded $3.9 Million RO1 NIH Grant to Advance Innovative Hepatitis Program 2
(Date:10/22/2014)... 2014 On Saturday, October 25, 2014, the ... family health and fitness fair ¡Vive tu vida! Get Up! ... good nutrition for better health and wellness for people of ... and open to the public, will be held at Dean ... am to 1:00 pm. , “¡Vive tu Vida! Get ...
(Date:10/22/2014)... Medical Solutions , the ... to announce that our co-founder and CFO, Scott ... Staffing 100 for 2014. Anderson was also named ... people in the staffing industry,” in 2013.     , ... healthcare staffing company in the U.S., was named ...
(Date:10/22/2014)... Va. (PRWEB) October 22, 2014 For Dr. ... to make money; it’s an extension of her life’s mission. ... latest venture as the owner of FirstLight HomeCare, make it ... “It’s important to me that my work makes a difference ... harbored an entrepreneurial spirit, so after much research, I felt ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- The United ... arriving from Ebola-affected nations of West Africa land ... them for infection with the virus. In ... Johnson noted that 94 percent of air passengers ... at one of these five airports -- New ...
(Date:10/22/2014)... RESTON, Va. (PRWEB) October 22, 2014 ... Healthcare Innovation , which is dedicated to distribute ... efficiency of healthcare delivery worldwide announced the development ... in which patients expect when receiving healthcare. These ... definition for patient-centered care: “providing care that is ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 2Health News:Medical Solutions Co-Founder/CFO Scott Anderson Named to Staffing Industry Analysts’ 2014 Staffing 100 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2
... Granada and Edimbourgh have developed a new therapy for ... as it has not cause side effects. This ... (palladium) into microspheres, to synthesize artificial materials or activate ... system captures palladium within its microstructure. Palladium is a ...
... Scientists from the Hebrew University have identified the molecular basis ... of this research have just been published in the journal ... entire genetic information required for building the proteins of the ... changes in the cell function. These changes can lead to ...
... French scientists (from the Unit of Research on Nutritional ... the French Institute for Prevention and Health Education, St. ... published a paper in the Canadian Medical Association ... and the relation of alcohol to cancer. They ...
... A new study of the brain,s master circadian clock ... a key pattern of rhythmic neural activity begins to decline ... Chancellor Gene Block, may have implications for the large number ... time changes. "Aging has a profound effect ...
... By Alan Mozes HealthDay Reporter , MONDAY, ... the mid-1990s, powerful antiretroviral therapies have radically improved the ... Now, research suggests that when made affordable ... for African patients. The finding stems from a ...
... , TUESDAY, July 19 (HealthDay News) -- Following ... meditation for a long time have more gray matter in ... also shrink less as they age and they have stronger ... cells may better relay electrical signals, researchers said. "Our ...
Cached Medicine News:Health News:A new therapy without side effects could improve dramatically chemotherapy 2Health News:Hebrew U. scientists identify molecular basis for DNA breakage 2Health News:Are drinking guidelines adequate regarding the risk of cancer? 2Health News:Are drinking guidelines adequate regarding the risk of cancer? 3Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 2Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 3Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 4Health News:Study shows new evidence of age-related decline in the brain's master circadian clock 5Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 2Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 3Health News: Drugs Can Bring HIV-Infected Africans Normal Life Spans 4Health News:Does Meditation Boost Brain Health? 2
... and quantification of proteinase 3 autoantibodies ... indirect immunofluorescence.Follow-up control of disease activity ... Anti-MPO-ELISA for detection of myeloperoxidase autoantibodies ... can be used from either of ...
... DYONICS POWERMAX Shaver Handpiece has 25% more ... standard Smith & Nephew handpiece providing optimal ... handling and reduced hand fatigue. ,The forward/reverse ... suction lever are all co-located to allow ...
... Light Source. , ... to provide every patient with ... through our ongoing research and ... and diagnostic solutions., ,At ...
The Linvatec 3mm and 5mm Universal Light Guides are autoclavable. They offer flexibility, superior light transmission, and universal fittings in a lightweight package....
Medicine Products: